pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›BACLOFEN
drug
save

BACLOFEN

Marketedupdated 3mo ago
by Beximco Pharmaceuticals USA Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 4
  • tagApproval4 co-mentions · 2 sources
  • companyAurobindo Pharma Ltd2 co-mentions · 2 sources
  • tagSmall Molecule2 co-mentions · 2 sources
  • tagRecall1 co-mentions · 1 sources

indications

investigational
Multiple Sclerosis

all catalysts(2)

approval · 2
Jul 13, 2021
approval
5y ago
BACLOFEN — FDA approval
BACLOFEN
→
Nov 21, 2025
approval
9mo ago
BACLOFEN — FDA approval
BACLOFEN
→

Trials studying BACLOFEN

  • phase4Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatmentcompletedn=184
  • phase3A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosisnot yet recruitingn=442
  • phase1Comparative Bioavailability Study of Baclofen 20 mg Tablets in Healthy Male Volunteers / Fasting Statecompletedn=27

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 8, 2037
~11.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Sep 29, 2041formulationUS 11491125
  • Sep 29, 2041formulationUS 11491125
  • Sep 29, 2041formulationUS 11491125
  • Sep 29, 2041formulationUS 11850225
  • Sep 29, 2041formulationUS 11850225
  • Sep 29, 2041formulationUS 11850225
  • Aug 30, 2039method-of-use (U-2779)US 10610502
  • Jul 29, 2039formulationUS 10792262
  • Jul 29, 2039formulationUS 10792262
  • Jul 29, 2039formulationUS 10792262
  • Jul 29, 2039formulationUS 11654124
  • Jul 29, 2039formulationUS 11654124
  • Jul 29, 2039formulationUS 11654124
  • Jul 29, 2039formulationUS 11931328
  • Jul 29, 2039formulationUS 11931328
  • Jul 29, 2039formulationUS 11931328
  • Sep 29, 2037formulationUS 11324696
  • Sep 8, 2037method-of-use (U-3433)US 11446246

News(0)

no news has mentioned this drug yet

brand
BACLOFEN
generic
BACLOFEN
indication
Muscle Spasticity
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?